CSL Announces $1.5 Billion U.S. Investment to Expand Plasma-Derived Therapies Capacity

Australian biotech giant CSL Limited has unveiled plans to invest $1.5 billion in the United States over the next five years to expand production of plasma-derived therapies and reinforce the country’s pharmaceutical supply chain. The investment is expected to create hundreds of high-quality jobs, although the company has not yet disclosed the exact locations of the new facilities. CSL currently operates major plants in Illinois and North Carolina, supporting its extensive global plasma collection and manufacturing network.

Strengthening U.S. Biopharma Manufacturing Capabilities

The expansion underscores CSL’s commitment to meeting rising global demand for plasma-based medicines used in immunodeficiencies, bleeding disorders, and other rare conditions. With its established operational footprint in North America, the investment further positions CSL as a key contributor to U.S. healthcare resilience and domestic biopharmaceutical capacity.

CSL’s Market Position and Financial Strength

CSL is among the world’s largest biotechnology companies, operating through CSL Behring, CSL Seqirus, and CSL Vifor. The group generates roughly half of its revenue in North America and maintains strong profitability and steady revenue growth. With a market capitalization of $57.56 billion, CSL’s diversified portfolio, from plasma therapies to influenza vaccines and nephrology treatments, supports sustained long-term expansion and global competitiveness.